

Press release

Nanocarriers for Effective Drug Delivery of Therapeutic Peptides

Strategic collaboration between the two biopharmaceutical companies Rodos Biotarget GmbH and PHARIS Biotec GmbH, both headquartered in Hannover, Germany.

Hannover, 25 July 2016. Rodos Biotarget GmbH, specialists for advanced drug delivery technologies applying nanocarriers, and PHARIS Biotec GmbH, a pioneer in the area of therapeutic peptides, have signed an agreement to start strategic collaboration. The two biopharmaceutical companies based in Hannover will combine their expertise to optimize galenic formulations.

Therapeutic peptides are highly potent drugs exhibiting specific mechanisms of action. PHARIS Biotec GmbH has a portfolio of candidates from this promising class of drugs for the treatment of viral infections, cancer and autoimmune diseases. With their TargoSpheres, Rodos Biotarget develops nanocarriers to optimize the transport of such damage-sensitive drugs within the organism.

Wolf-Georg Forssmann, MD and CEO of PHARIS Biotec GmbH explains: “By loading our therapeutic peptides in Rodos’ nanocarriers we intend to optimize their efficacy in order to enhance patient compliance.” “PHARIS is the ideal partner to address this important drug class using nanocarriers”, says Marcus Furch, PhD and CEO of Rodos Biotarget GmbH, “At the same time, we can focus on selective and highly specific therapies”.

About Biotarget GmbH

Rodos Biotarget GmbH is a biopharmaceutical company that joins the ranks of industry leadership in nanocarriers for drug delivery. Rodos has developed the versatile TargoSphere[®] platform technology comprising biocompatible and biodegradable nanocarriers. These are designed to achieve enhanced prophylactic and therapeutic approaches against diseases of high and unmet medical need like cancers, chronic infections, autoimmune diseases, and neurological diseases. Rodos Biotarget offers TargoSphere[®] to the pharmaceutical industry as a “construction kit”: Specific additives and components of the nanocarriers can be tailored to suit the respective medical objective. The spherical body can be tuned to prolong blood circulation and/or sustained release of the drug payload. Targeting ligands located on the nanocarrier’s surface permit specific delivery of the drug within close proximity to target cells and/or allow for the selective uptake of encapsulated actives into such cells. Rodos nanocarriers aim to improve a drug’s pharmacokinetics, pharmacodynamics, and safety profile, and they also allow for line and label extensions. Rodos pushes the commercialization of its patented technology platform with two in-house therapeutic applications: TargoBiotics[™] for the treatment of intracellular bacterial infections, and TargoVir[™] for the treatment of devastating viral diseases.

About PHARIS Biotec GmbH

PHARIS Biotec GmbH is working with the concept of its own developed method of using peptides and proteins naturally produced by the human organism as agents so that they can be used as an appropriate form of medication. Originating from the applied research carried out at the Lower Saxony Institute of Peptide Research (IPF) in Hannover – up to its privatization in 2000 as an institution of the State of Lower Saxony and research institute attached to Hannover Medical School – the work of the PHARIS Group focuses on the discovery and development of innovative drugs, particularly for the therapy of diseases of the cardiovascular and renal system, of hormone

and metabolic disorders and of nervous and skin syndromes. Further projects are related to tumor and infectious diseases.

The forms of administration for drugs from naturally produced peptides and naturally occurring substances should be optimized so that the highest level of efficacy can be facilitated. PHARIS should thus achieve sustainability.

Additional Information: <http://www.biotargeting.eu> and <http://www.pharis.de>

Contacts

Rodos Biotarget GmbH:

Medical Park Hannover
Feodor-Lynen-Str. 31
D-30625 Hannover / Germany
Tel.: +49 (511) 7273 8835
Fax: +49 (511) 214 7076
m.furch@biotargeting.eu

Contact for Press Representatives (Rodos Biotarget GmbH):

WeichertMehner Unternehmensberatung für Kommunikation & Co. KG
Mathias Rentsch
Tel.: +49 (351) 5014 0200
mathias.rentsch@weichertmehner.com

PHARIS Biotec GmbH:

Medical Park Hannover
Feodor-Lynen-Str. 31
D-30625 Hannover / Germany
Tel.: +49 (511) 7273 8835
Fax: +49 (511) 214 7076
wg.forssmann@pharis.de and b.gillmann@pharis.de